Cover Image
市場調查報告書

異位性皮膚炎:流行病學·基於患者之市場預測,治療流程,上市藥·開發平台藥物分析

Atopic dermatitis: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis

出版商 Datamonitor Healthcare 商品編碼 365198
出版日期 內容資訊 英文 184 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
異位性皮膚炎:流行病學·基於患者之市場預測,治療流程,上市藥·開發平台藥物分析 Atopic dermatitis: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis
出版日期: 2016年01月01日 內容資訊: 英文 184 Pages
簡介

本報告提供異位性皮膚炎治療藥市場相關調查分析,市場預測,治療,流行病學,上市藥,開發平台藥物趨勢等系統性資訊。

預測:異位性皮膚炎

  • 摘要整理
  • 市場概要·趨勢
  • 市場定義·手法
  • crisaborole
  • dupilumab
  • Elidel (pimecrolimus)
  • Elocon (mometasone furoate)
  • Protopic (tacrolimus)
  • 1次調查手法

治療:異位性皮膚炎

  • 摘要整理
  • 1次調查手法
  • 疾病定義·診斷
  • 患者區分
  • 各國治療樹
  • 目前治療選擇
  • 處方趨勢
  • 持續性與合法性
  • 未滿足需求
  • 處方的影響
  • 開發平台藥物與未來的治療

流行病學:異位性皮膚炎

  • 摘要整理
  • 資訊來源·手法
  • 預測
  • 流行病學者的考察
  • 優點·缺點

上市藥:異位性皮膚炎

  • 摘要整理
  • 產品概要
  • 產品簡介:Elidel
  • 產品簡介:Elocon
  • 產品簡介:Medrol
  • 產品簡介:Protopic
  • 產品簡介:Toctino

開發平台:異位性皮膚炎

  • 摘要整理
  • 臨床實驗平台概要
  • 產品簡介 (後期) :crisaborole
  • 產品簡介 (後期) :dupilumab

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC5466

Dupilumab is expected to be the first biologic approved for atopic dermatitis, offering a novel treatment option for the most severe patients and driving a strong CAGR of 15.6% during the 2015-24 forecast period.

This report addresses the following questions:

  • Where is the untapped commercial opportunity in the atopic dermatitis market?
  • How will the late-phase candidates dupilumab and crisaborole fit into the existing atopic dermatitis treatment algorithm?
  • What do surveyed dermatologists consider to be the greatest unmet needs in atopic dermatitis?
  • What role does pricing and reimbursement play in prescribing for atopic dermatitis and what impact will the launch of new therapies have on this?
  • How do prescribing patterns change as disease severity increases?

TABLE OF CONTENTS

FORECAST: ATOPIC DERMATITIS

  • 1. Executive Summary
  • 2. Market Overview and Trends
  • 3. Market Definition and Methodology
  • 4. crisaborole
  • 5. dupilumab
  • 6. Elidel (pimecrolimus)
  • 7. Elocon (mometasone furoate)
  • 8. Protopic (tacrolimus)
  • 9. Primary Research Methodology

TREATMENT: ATOPIC DERMATITIS

  • 10. Executive Summary
  • 11. Primary Research Methodology
  • 12. Disease Definition and Diagnosis
  • 13. Patient Segmentation
  • 14. Country Treatment Trees
  • 15. Current Treatment Options
  • 16. Prescribing Trends
  • 17. Persistence and Compliance
  • 18. Unmet Needs in Atopic Dermatitis
  • 19. Prescribing Influences
  • 20. Pipeline Drugs and Future Treatment

EPIDEMIOLOGY: ATOPIC DERMATITIS

  • 21. Executive Summary
  • 22. Sources and Methodology
  • 23. Forecast
  • 24. Epidemiologist Insight
  • 25. Strengths and Limitations

MARKETED DRUGS: ATOPIC DERMATITIS

  • 26. Executive Summary
  • 27. Product Overview
  • 28. Product profile: Elidel
  • 29. Product profile: Elocon
  • 30. Product profile: Medrol
  • 31. Product profile: Protopic
  • 32. Product profile: Toctino

PIPELINE: ATOPIC DERMATITIS

  • 33. Executive Summary
  • 34. Clinical Pipeline Overview
  • 35. Product profile (late stage): crisaborole
  • 36. Product profile (late stage): dupilumab
Back to Top